E2730 manufacturers
- E2730
-
- $1520.00
-
2026-05-11
- CAS:1520073-91-9
- Purity: 98.54%
- Supply Ability: 10g
|
| Product Name: | E2730 | | Synonyms: | E2730;Sulfamide, N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]- | | CAS: | 1520073-91-9 | | MF: | C9H8F4N2O2S | | MW: | 284.23 | | EINECS: | | | Product Categories: | | | Mol File: | 1520073-91-9.mol |  |
| | E2730 Chemical Properties |
| Boiling point | 367.340±52.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.651±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 7.803±0.40(predicted) |
| | E2730 Usage And Synthesis |
| Uses | E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg)[1]. | | References | [1] Fukushima K, et al. Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medication. Epilepsia Open. 2023 Sep;8(3):834-845.. DOI:10.1002/epi4.12741 |
| | E2730 Preparation Products And Raw materials |
|